Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET
Company Participants
Diane Weiser – Senior Vice President, Corporate Affairs
Robert Blum – President & Chief Executive Officer
Andrew Callos – Executive Vice President & Chief Commercial Officer
Fady Malik – Executive Vice President, R&D
Isaac Ciechanover – EVP Corporate Development and Chief Business Officer
Stuart Kupfer – Senior Vice President & Chief Medical Officer
Sung Lee – Executive Vice President & Chief Financial Officer
Conference Call Participants
Sean McCutcheon – Raymond James
Salim Syed – Mizuho
Gena Wang – Barclays
Paul Choi – Goldman Sachs
Cory Kasimov – Evercore ISI
Roanna Ruiz – Leerink Partners
Akash Tewari – Jefferies
Charles Duncan – Cantor Fitzgerald
Tessa Romero – JPMorgan
Maxwell Skor – Morgan Stanley
David Lebowitz – Citigroup Inc.
Mayank Mamtani – B. Riley Securities
Srikripa Devarakonda – Truist Securities
James Condulis – Stifel
Jason Zemansky – Bank of America
Leland Gershell – Oppenheimer
Jason Butler – Citizens JMP
John Gionco – Needham & Company
Yasmeen Rahimi – Piper Sandler
Operator
Good afternoon, and welcome to Cytokinetics’ First Quarter 2025 Conference Call. At this time, I would like to inform you that this call is being recorded. And all participants are in a listen-only mode. At the company’s request, we will open the call to questions after the presentation. We will allow for only one question per participant.
I will now turn the call over to Diane Weiser, Cytokinetics’ Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; Andrew Callos, EVP and Chief Commercial Officer will address commercial readiness activities for aficamten; Fady Malik, EVP of R&D, will provide updates related to clinical development
#Cytokinetics #Incorporated #CYTK #Earnings #Call #Transcript